Management of resectable gastrointestinal stromal tumor.
Gastrointestinal stromal tumor (GIST) is a rare neoplasm that recently has become an intense focus of scientific investigation, as it serves as a model for the molecular therapy for cancer. Although surgery remains the principle treatment of primary localized GIST, imatinib mesylate, a selective inhibitor of KIT protein, achieves dramatic responses in metastatic GIST. Multimodality therapy integrating surgery and molecular therapy has shown promise. This article summarizes the epidemiology, clinicopathologic features, natural history, and clinical management of GIST.
Chaudhry
Umer I
UI
Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, Box 203, 1275 York Avenue, New York, NY 10021, USA.
DeMatteo
Ronald P
RP
D001549:Benzamides; D003131:Combined Modality Therapy; D019468:Disease Management; D046152:Gastrointestinal Stromal Tumors / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D020794:Receptor Protein-Tyrosine Kinases